US 11,730,725 B2
Niraparib formulations
Simon McGurk, Falmouth, ME (US); Padma Narayan, Brookline, MA (US); and Aleksandar Rajlic, Brookline, MA (US)
Assigned to Tesaro, Inc., Wilmington, DE (US)
Appl. No. 16/650,948
Filed by Tesaro, Inc., Waltham, MA (US)
PCT Filed Sep. 26, 2018, PCT No. PCT/US2018/052979
§ 371(c)(1), (2) Date Mar. 26, 2020,
PCT Pub. No. WO2019/067634, PCT Pub. Date Apr. 4, 2019.
Claims priority of provisional application 62/563,535, filed on Sep. 26, 2017.
Prior Publication US 2020/0289494 A1, Sep. 17, 2020
Int. Cl. A61K 31/454 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01)
CPC A61K 31/454 (2013.01) [A61K 9/1652 (2013.01); A61K 9/5026 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01)] 15 Claims
 
1. A pharmaceutical composition in the form of a tablet comprising the following components on a weight percentage basis:
(i) in an intragranular portion:
(a) 40-50% of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole 7-carboxamide 4-methylbenzenesulfonate monohydrate;
(b) 9-11% of a first diluent;
(c) 30-40% of a second diluent;
(d) 1-3% of a binder;
(e) 0.1-2% of a disintegrant;
(f) 2-4% of a glidant, adsorbent, or absorbent; and
(g) 0.1-2% of a lubricant; and
(ii) in an extragranular portion:
(a) 0.1-2% of a disintegrant;
(b) 0.1-2% of a glidant, adsorbent, or absorbent; and
(c) 0.1-2% of a lubricant.